Cardiac monocytes and macrophages after myocardial infarction.
Peet C, Ivetic A, Bromage DI, Shah AM. · 2020
Read Cardiac monocytes and macrophages after myocardial infarction. by Peet C, Ivetic A, Bromage DI, Shah AM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7177720.txt.
Introduction
Peet and co-authors review the role of monocytes and macrophages after a heart attack. Their article appeared in Cardiovascular Research. These immune cells arrive at the injured heart muscle in large numbers. They help clear dead cells and lay down scar tissue. That repair work is vital in the first days. But poor control of these cells can drive harmful remodeling of the heart. The result can be heart failure.
Older models split macrophages into two fixed types. One type drives inflammation, and the other drives repair. Newer work shows far more variety and change in these cells. The authors weigh mouse studies against human data. They also ask why broad immune suppression has failed in trials. Targeted treatment will need a finer grasp of cell states, they argue. Readers get a clear account of a fast-changing field and its stakes for care after heart attack.
Catalog record
| CREATOR | Peet C, Ivetic A, Bromage DI, Shah AM. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cardiac monocytes and macrophages after myocardial infarction By Claire Peet, Aleksandar Ivetic, Daniel I Bromage, Ajay M Shah Published in: Cardiovascular Research DOI: 10.1093/cvr/cvz336 ABSTRACT Abstract Improvements in early interventions after acute myocardial infarction (AMI), notably, the increased use of timely reperfusion therapy, have increased survival dramatically in recent decades. Despite this, maladaptive ventricular remodelling and subsequent heart failure (HF) following AMI remain a significant clinical challenge, particularly because several pre-clinical strategies to attenuate remodelling have failed to translate into clinical practice. Monocytes and macrophages, pleiotropic cells of the innate immune system, are integral in both the initial inflammatory response to injury and subsequent wound healing in many tissues, including the heart. However, maladaptive immune cell behaviour contributes to ventricular remodelling in mouse models, prompting experimental efforts to modulate the immune response to prevent the development of HF. Seminal work in macrophage biology defined macrophages as monocyte-derived cells that are comprised of two populations, pro-inflammatory M1 macrophages and reparative M2 macrophages, and initial investigations into cardiac macrophage populations following AMI suggested they aligned well to this model. However, more recent data, in the heart and other tissues, demonstrate remarkable heterogeneity and plasticity in macrophage development, phenotype, and function. These recent insights into macrophage biology may explain the failure of non-specific immunosuppressive strategies and offer novel opportunities for therapeutic targeting to prevent HF following AMI. Here, we summarize the traditional monocyte-macrophage paradigm, experimental evidence for the significance of these cells in HF after AMI, and the potential relevance of emerging evidence that refutes canonical models of monocyte and macrophage biology. Keywords: Monocyte, Macrophage, Myocardial infarction INTRODUCTION Emergency management of acute myocardial infarction (AMI) has been revolutionized by timely reperfusion therapy and, in particular, increasing access to primary percutaneous coronary intervention, leading to dramatic improvements in early survival.1–3 Despite this, AMI remains the commonest cause of heart failure (HF) and HF-related morbidity and mortality following AMI remain high.4–7 In view of the burden of HF following AMI, there is an unmet need for better understanding of the pathogenesis of ventricular remodelling and development of novel therapeutic targets. In AMI, reduced blood flow to a region of myocardium results in infarction, mediated mainly through oncosis and necrosis.8 This necrotic myocardium becomes a region of mechanical weakness that requires scar deposition to prevent myocardial rupture and limit functional deterioration. This adaptive remodelling is necessary to prevent early mortality following AMI. However, excessive and progressive (maladaptive) ventricular remodelling, at both the infarct site and remote myocardium, alters ventricular size and function, culminating in the clinical syndrome of HF. Understanding the balance between adaptive and maladaptive remodelling is an emerging research area that has the potential to identify novel therapeutic targets for the prevention of HF after myocardial infarction (MI). The innate immune response is an important regulator of this process and comprises three key phases: the inflammatory, proliferative, and maturation phases.8–10 Cell death triggers sterile inflammation, through exposure of endogenous damage-associated molecular patterns (DAMPs) to the innate immune system. Recognition of DAMPs by pattern recognition receptors on resident innate immune cells prompts a cascade of chemokine and pro-inflammatory cytokine release, recruiting and activating neutrophils, monocytes, and macrophages. Together, these cells degrade the extracellular matrix and phagocytose necrotic cells. This initial inflammatory phase, which peaks around Day 3 post-injury, is followed by a longer proliferative phase lasting around 10 days, also mediated by immune cells. This phase is characterized by anti-inflammatory signalling, fibroblast proliferation, and deposition of granulation tissue. The final, maturation phase occurs over subsequent months and is characterized by remodelling of the extracellular matrix, with few immune cells present at the site of injury. During this period following AMI, there are significant changes to ventricular size, shape, and function, with maladaptive remodelling leading to the development of HF.11 Monocytes and macrophages are implicated at all three stages of this response. Cardiac monocyte and macrophage numbers expand rapidly in the days following AMI.12,13 These initial, infiltrating populations demonstrate a pro-inflammatory phenotype which shifts over the ensuing days to a predominantly reparative phenotype, coordinating the deposition of scar tissue.14 By 2 weeks post-AMI, monocyte and macrophage populations at the site of infarction return to baseline, although macrophages persist for months after AMI in the remote, remodelling myocardium.15 Nonetheless, numerous trials of immunosuppressive agents have failed to mitigate HF following AMI, which is unsurprising given the complex interplay of reparative and deleterious processes, and demonstrates the need for a more detailed understanding of cellular and molecular pathways in ventricular remodelling to facilitate more targeted therapeutic interventions.16–18 The putative role of monocytes and macrophages in healing post-AMI, and the persistence of macrophages in remodelling ventricular myocardium, has led to interest in targeting these cells to prevent maladaptive remodelling. However, various strategies to target specific sub-populations have delivered seemingly contradictory results. This may relate to an overly constrictive traditional understanding and definitions of macrophage subsets, which are increasingly understood to be heterogeneous and plastic, impeding focused investigation of their role in ventricular remodelling after AMI. Here, we discuss the canonical view of monocyte-derived macrophage differentiation and activation, and how strategies targeting monocyte and macrophage populations have impacted on ventricular remodelling in pre-clinical models. We then discuss emerging data on the complexity of macrophage development and phenotype that challenges the existing paradigm and may justify disparities in existing evidence. Finally, we discuss how recognition of macrophage heterogeneity and plasticity may benefit ongoing investigation and the development of new treatments in this important clinical area. TRADITIONAL VIEWS OF CARDIAC MONOCYTE AND MACROPHAGE POPULATIONS 2.1 Monocyte and macrophage classification The mononuclear phagocyte system is a family of myeloid cells comprising monocytes, macrophages, and dendritic cells. Monocytes are short-lived circulating cells that are implicated in inflammation through both direct effects and by differentiation into dendritic cells and macrophages. These cells develop from the common myeloid progenitor in the bone marrow and are released into the circulation, where they comprise two main subsets: conventionally known as classical and non-classical. These populations were originally described in humans, defined by CD16 (cluster of differentiation 16) expression, and later in mice. Phenotypic profiling suggests that these populations correspond, facilitating experimental characterization of populations in human studies.19,20 Classical monocytes, typically described as CD14+CD16neg in humans and Ly-6Chigh in mice, are implicated in inflammation.21,22 These cells are released from the bone marrow and extramedullary sites of haematopoiesis, such as the spleen, and traffic to sites of injury in a CCR2 [chemokine (C-C motif) receptor 2] dependent manner, and comprise over 90% of circulating monocytes.22 Upon extravasation, classical monocytes contribute to the innate immune response both via direct effects, such as tumour necrosis factor α (TNF-α) and nitric oxide production, and indirectly, by differentiation into macrophages and dendritic cells.23 More recently, these cells have been shown to play an important role in activating the adaptive immune response, through antigen presentation to T cells.23 In contrast, non-classical monocytes (CD14+CD16+/Ly-6Clow) are thought to persist in the circulation and their role in inflammation is less clear. In mice, these cells have been demonstrated to arise in an NR4A1 (nuclear receptor subfamily four group A member one) dependent manner, a transcription factor which is dispensable for classical monocyte development.24,25 Both murine and human non-classical monocytes may be differentiated from classical monocytes by high levels